Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2010-12-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism
NCT02692885
The Role of Brown Adipose Tissue in Triglyceride Clearance in People
NCT02786251
Body Heat Content and Dissipation in Obese and Normal Weight Adults
NCT00266500
FFA Metabolism in Different Types of Human Obesity
NCT00068900
Epigenetic Regulation of Human Adipose Tissue Distribution
NCT02728635
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy subjects
18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body mass index from 20 to 27.
15N-Thymidine, 2H-Water
Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).
Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
15N-Thymidine, 2H-Water
Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).
Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy.
Exclusion Criteria
* Illicit substance or alcohol abuse.
* Body mass index \> 27 kg/meters squared.
* Underweight (BMI \< 20 kg/m2).
* History of keloid formation (excessive scarring).
* Pregnant.
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brigham and Women's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthew Steinhauser, MD
Attending Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew L Steinhauser, MD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Steinhauser ML, Bailey AP, Senyo SE, Guillermier C, Perlstein TS, Gould AP, Lee RT, Lechene CP. Multi-isotope imaging mass spectrometry quantifies stem cell division and metabolism. Nature. 2012 Jan 15;481(7382):516-9. doi: 10.1038/nature10734.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BWH-2010p001900
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.